SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-006285 to PRECISION BIOSCIENCES INC (DTIL) (CIK 0001357874) (DTIL)

PRECISION BIOSCIENCES INC (DTIL) (CIK 0001357874)
Date: June 12, 2023 · CIK: 0001357874 · Accession: 0000000000-23-006285

AI Filing Summary & Sentiment

File numbers found in text: 333-272540

Date
June 12, 2023
Author
Not clearly detected
Form
UPLOAD
Company
PRECISION BIOSCIENCES INC (DTIL) (CIK 0001357874)

Letter

United States securities and exchange commission logo June 12, 2023 Michael Amoroso President and Chief Executive Officer Precision BioSciences, Inc. 302 East Pettigrew St., Suite A-100 Durham, North Carolina 27701 Re:Precision BioSciences, Inc. Registration Statement on Form S-3 Filed June 9, 2023 File No. 333-272540 Dear Michael Amoroso: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Peter N. Handrinos, Esq.

Show Raw Text
United States securities and exchange commission logo
June 12, 2023
Michael Amoroso
President and Chief Executive Officer
Precision BioSciences, Inc.
302 East Pettigrew St., Suite A-100
Durham, North Carolina 27701
Re:Precision BioSciences, Inc.
Registration Statement on Form S-3
Filed June 9, 2023
File No. 333-272540
Dear Michael Amoroso:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Peter N. Handrinos, Esq.